We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
deCODE Chemistry and FSMA Announce Extension of Research Agreement
News

deCODE Chemistry and FSMA Announce Extension of Research Agreement

deCODE Chemistry and FSMA Announce Extension of Research Agreement
News

deCODE Chemistry and FSMA Announce Extension of Research Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "deCODE Chemistry and FSMA Announce Extension of Research Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

deCODE chemistry and Families of Spinal Muscular Atrophy (FSMA) have announced a renewal of their collaboration to develop a small molecule therapeutic for spinal muscular atrophy.

Initiated in 2003, the deCODE chemistry-FSMA collaboration focused on optimization of a class of molecule that was discovered in a high-throughput, cell-based phenotypic assay developed under sponsorship by FSMA.

The focus of the collaboration in the coming year will be to further assess the pharmaceutical properties of lead candidates and select a small number of analogues for IND-directed, pre-clinical development.

"We are pleased to continue our collaboration with FSMA on this important program," said Dr. David Zembower, Vice President of Chemistry at deCODE chemistry.

"We are encouraged by the progress that has been made over the past year, and look forward to working with FSMA to help them achieve their goals."

"There has been much progress in SMA research since our relationship with deCODE began, and we are proud that our collaborative effort has been a part of that," said Dr. Jill Jarecki, FSMA Research Director.

"We are confident that our pioneering endeavor has the potential to enable a novel treatment for SMA."

Advertisement